Trial Profile
Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 31 Jan 2009 New trial record